Merck Sharp + Dohme Corp.

Novartis Ag

Merck + Co., Inc.

Msd K.k.

Ifm Due, Inc.

Novartis Inflammasome Research, Inc.

Jason David Katz

William R Roush

Shankar Venkatraman

Hans Martin Seidel

Dong-Ming Shen

Hua Zhou

Shomir Ghosh

Joey Lee Methot

Jianmin Fu

Meredeth Ann McGowan

Gary D Glick

David Guenther Winkler

David Joseph Guerin

Abdelghani Achab

Matthew Christopher

Luigi Franchi

Anthony William Opipari, Jr

Christopher J Dinsmore

Christopher Francis Thompson

Norman Kong

James Patrick Jewell

Mark E Scott

Peter H Fuller

Kin Chiu Fong

Shimin Xu

Luis E Torres

Hongbo Zeng

Danielle Falcone

Yumei Liu

Yunfeng Bai

Zhixiang Zheng

Neville J Anthony

Jason D Brubaker

Solomon D Kattar

Yongqi Deng

Matthew Lloyd Childers

Qinglin Pu

Francesc Xavier Fradera Llinas

Changwei Mu

Chaomin Li

Yabin Li

Lihu Yang

Michael D Altman

David James Witter

Hongjun Zhang

Joshua Close

Jonathan R Young

Rong Zhang

Joon Jung

Xavier Fradera

Feng Shi

Kathryn Ann Lipford

Ning Fu

Ravi Kurukulasuriya

Xiaoli Zhao

Yudith Garcia

Xiansheng Leng

Baijun Ye

Sixing Zhang

Matthew G Stanton

Timothy J Guzi

Jongwon Lim

David L Sloman

Phieng Siliphaivanh

Michelle R Machacek

Ryan D Otte

Tony Siu

John W Lampe

Sandra Lee Knowles

Wei Deng

Satoru Ito

Yuan Tian

Jiaqiang Cai

Liping Yang

Graham Frank Smith

Michelle Martinez

Rachel Nicola MacCoss

Hyun Chong Woo

Scott Peterson

Xiaoxing Du

Njamkou Noucti

Ana Esther Gabarda Ortega

Deqian Bian

Meredeth A Mcgowan

Luis Torres

Xiaona Wang

Chonggang Wang

Yongquan Hou

Xichao Wang

Guoquan Xu

Neville John Anthony

Abdelghani A Achab

Abdelghani Abe Achab

Anthony William Opipari Jr

Anthony William Opipari

Sandra L Knowles

Matthew P Christopher

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Compounds and compositions for treating conditions associated with NLRP activity

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) having formula (I) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

Compounds and compositions for treating conditions associated with STING activity

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein. Compounds AA are modulators of NLRP1 and/or NLRP3

Sulphonamides and compositions thereof for treating conditions associated with NLRP activity

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g. osteoarthritis, osteoporosis or osteopetrosis disorders), eye disease (e.g. glaucoma or macular degeneration), a disease caused by viral infection (e.g. HIV or AIDS), an autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematosus or Autoimmune Thyroiditis), cancer or aging. 

The instant invention provides compounds of formulas Ia and Ib which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer. 

Purine inhibitors of human phosphatidylinositol 3-kinase delta

The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: 

The instant invention provides compounds of formula (I) which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer. 

The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors

Growing community of inventors

Newton Highlands, MA, United States of America

Jason David Katz